Polyclonal CDK8 Antibody

<strong>Polyclonal CDK8 Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2016992_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 5 µL_x000D_ <strong>Molecular Weight or Concentration:</strong> 60 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20¬∞C_x000D_ <strong>Keywords:</strong> K35_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Ding X, Sharko AC, McDermott MSJ, Schools GP, Chumanevich A, Ji H, Li J, Zhang L, Mack ZT, Sikirzhytski V, Shtutman M, Ivers L, O'Donovan N, Crown J, Gy≈ërffy B, Chen M, Roninson IB, Broude EV. Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in¬†vitro and in¬†vivo Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2201073119._x000D_ 2: Leclerc V, L√©opold P. The cyclin C/Cdk8 kinase Prog Cell Cycle Res. 1996;2:197-204._x000D_ 3: Hofmann MH, Mani R, Engelhardt H, Impagnatiello MA, Carotta S, Kerenyi M, Lorenzo-Herrero S, B√∂ttcher J, Scharn D, Arnhof H, Zoephel A, Schnitzer R, Gerstberger T, Sanderson MP, Rajgolikar G, Goswami S, Vasu S, Ettmayer P, Gonzalez S, Pearson M, McConnell DB, Kraut N, Muthusamy N, Moll J. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance Mol Cancer Ther. 2020 Apr;19(4):1018-1030._x000D_ 4: Sharko AC, Lim CU, McDermott MSJ, Hennes C, Philavong KP, Aiken T, Tatarskiy VV, Roninson IB, Broude EV. The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs Cells. 2021 Jan 12;10(1):144._x000D_ 5: McCleland ML, Soukup TM, Liu SD, Esensten JH, de Sousa e Melo F, Yaylaoglu M, Warming S, Roose-Girma M, Firestein R. Cdk8 deletion in the Apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis J Pathol. 2015 Dec;237(4):508-19._x000D_ 6: Song W, Wu S, Wu Q, Zhou L, Yu L, Zhu B, Gong X. The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab J Cell Biochem. 2019 Aug;120(8):14095-14106._x000D_ 7: K√∂hler K, Sanchez-Pulido L, H√∂fer V, Marko A, Ponting CP, Snijders AP, Feederle R, Schepers A, Boos D. The Cdk8/19-cyclin C transcription regulator functions in genome replication through metazoan Sld7 PLoS Biol. 2019 Jan 29;17(1):e2006767._x000D_ 8: Xu W, Wang Z, Zhang W, Qian K, Li H, Kong D, Li Y, Tang Y. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/Œ≤-catenin signaling pathway Cancer Lett. 2015 Jan 28;356(2 Pt B):613-27._x000D_ 9: Lin HH, Khosla M, Huang HJ, Hsu DW, Michaelis C, Weeks G, Pears C. A homologue of Cdk8 is required for spore cell differentiation in Dictyostelium Dev Biol. 2004 Jul 1;271(1):49-58._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/31385392">10: Jezek J, Chang KT, Joshi AM, Strich R. Mitochondrial translocation of cyclin C stimulates intrinsic apoptosis through Bax recruitment EMBO Rep. 2019 Sep;20(9):e47425. </a>_x000D_ _x000D_ <strong>Products Related to Polyclonal CDK8 Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>